Outcomes in older adults with acute lymphoblastic leukaemia (ALL)

Results from the international MRC UKALL XII/ECOG2993 trial

Jonathan I. Sive, Georgina Buck, Adele Fielding, Hillard M. Lazarus, Mark R Litzow, Selina Luger, David I. Marks, Andrew Mcmillan, Anthony V. Moorman, Susan M. Richards, Jacob M. Rowe, Martin S. Tallman, Anthony H. Goldstone

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Although the incidence rate of acute lymphoblastic leukaemia (ALL) is slightly higher in older than in younger adults, response rates to induction chemotherapy and survival rates are poorer. The contribution of disease-related versus treatment-related factors remains unclear. We analysed 100 older patients (aged 55-65 years) treated on the UKALLXII/ECOG2993 trial compared with 1814 younger patients (aged 14-54 years). Baseline characteristics, induction chemotherapy course, infections, drug reductions and survival outcomes were compared. There were more Philadelphia-positive (Ph+) patients in the older group (28% vs. 17%, P = 0·02), and a trend towards higher combined cytogenetic risk score (46% vs. 35%, P = 0·07). The complete remission rate in older patients was worse (73% vs. 93%, P < 0·0001) as was 5-year overall survival (21% vs. 41%, P < 0·0001) and event-free survival (EFS) (19% vs. 37%, P < 0·0001). Older patients had more infections during induction (81% vs. 70%, P = 0·05), and drug reductions (46% vs. 28%, P = 0·0009). Among older patients, Ph+ and cytogenetic risk category as well as infection during induction predicted for worse EFS. Poorer outcomes in these patients are partly due to cytogenetic risk, but there is significant morbidity and mortality during induction chemotherapy with frequent delays and drug reductions. New approaches, including better risk stratification and use of targeted therapies, could improve treatment for these patients.

Original languageEnglish (US)
Pages (from-to)463-471
Number of pages9
JournalBritish Journal of Haematology
Volume157
Issue number4
DOIs
StatePublished - May 2012

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Induction Chemotherapy
Cytogenetics
Disease-Free Survival
Infection
Pharmaceutical Preparations
Survival
Young Adult
Therapeutics
Survival Rate
Morbidity
Mortality
Incidence

Keywords

  • Acute lymphoblastic leukaemia
  • Chemotherapy
  • Elderly
  • Infection

ASJC Scopus subject areas

  • Hematology

Cite this

Outcomes in older adults with acute lymphoblastic leukaemia (ALL) : Results from the international MRC UKALL XII/ECOG2993 trial. / Sive, Jonathan I.; Buck, Georgina; Fielding, Adele; Lazarus, Hillard M.; Litzow, Mark R; Luger, Selina; Marks, David I.; Mcmillan, Andrew; Moorman, Anthony V.; Richards, Susan M.; Rowe, Jacob M.; Tallman, Martin S.; Goldstone, Anthony H.

In: British Journal of Haematology, Vol. 157, No. 4, 05.2012, p. 463-471.

Research output: Contribution to journalArticle

Sive, JI, Buck, G, Fielding, A, Lazarus, HM, Litzow, MR, Luger, S, Marks, DI, Mcmillan, A, Moorman, AV, Richards, SM, Rowe, JM, Tallman, MS & Goldstone, AH 2012, 'Outcomes in older adults with acute lymphoblastic leukaemia (ALL): Results from the international MRC UKALL XII/ECOG2993 trial', British Journal of Haematology, vol. 157, no. 4, pp. 463-471. https://doi.org/10.1111/j.1365-2141.2012.09095.x
Sive, Jonathan I. ; Buck, Georgina ; Fielding, Adele ; Lazarus, Hillard M. ; Litzow, Mark R ; Luger, Selina ; Marks, David I. ; Mcmillan, Andrew ; Moorman, Anthony V. ; Richards, Susan M. ; Rowe, Jacob M. ; Tallman, Martin S. ; Goldstone, Anthony H. / Outcomes in older adults with acute lymphoblastic leukaemia (ALL) : Results from the international MRC UKALL XII/ECOG2993 trial. In: British Journal of Haematology. 2012 ; Vol. 157, No. 4. pp. 463-471.
@article{514af0c27b3d442dbb5008ed2cba4a6c,
title = "Outcomes in older adults with acute lymphoblastic leukaemia (ALL): Results from the international MRC UKALL XII/ECOG2993 trial",
abstract = "Although the incidence rate of acute lymphoblastic leukaemia (ALL) is slightly higher in older than in younger adults, response rates to induction chemotherapy and survival rates are poorer. The contribution of disease-related versus treatment-related factors remains unclear. We analysed 100 older patients (aged 55-65 years) treated on the UKALLXII/ECOG2993 trial compared with 1814 younger patients (aged 14-54 years). Baseline characteristics, induction chemotherapy course, infections, drug reductions and survival outcomes were compared. There were more Philadelphia-positive (Ph+) patients in the older group (28{\%} vs. 17{\%}, P = 0·02), and a trend towards higher combined cytogenetic risk score (46{\%} vs. 35{\%}, P = 0·07). The complete remission rate in older patients was worse (73{\%} vs. 93{\%}, P < 0·0001) as was 5-year overall survival (21{\%} vs. 41{\%}, P < 0·0001) and event-free survival (EFS) (19{\%} vs. 37{\%}, P < 0·0001). Older patients had more infections during induction (81{\%} vs. 70{\%}, P = 0·05), and drug reductions (46{\%} vs. 28{\%}, P = 0·0009). Among older patients, Ph+ and cytogenetic risk category as well as infection during induction predicted for worse EFS. Poorer outcomes in these patients are partly due to cytogenetic risk, but there is significant morbidity and mortality during induction chemotherapy with frequent delays and drug reductions. New approaches, including better risk stratification and use of targeted therapies, could improve treatment for these patients.",
keywords = "Acute lymphoblastic leukaemia, Chemotherapy, Elderly, Infection",
author = "Sive, {Jonathan I.} and Georgina Buck and Adele Fielding and Lazarus, {Hillard M.} and Litzow, {Mark R} and Selina Luger and Marks, {David I.} and Andrew Mcmillan and Moorman, {Anthony V.} and Richards, {Susan M.} and Rowe, {Jacob M.} and Tallman, {Martin S.} and Goldstone, {Anthony H.}",
year = "2012",
month = "5",
doi = "10.1111/j.1365-2141.2012.09095.x",
language = "English (US)",
volume = "157",
pages = "463--471",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Outcomes in older adults with acute lymphoblastic leukaemia (ALL)

T2 - Results from the international MRC UKALL XII/ECOG2993 trial

AU - Sive, Jonathan I.

AU - Buck, Georgina

AU - Fielding, Adele

AU - Lazarus, Hillard M.

AU - Litzow, Mark R

AU - Luger, Selina

AU - Marks, David I.

AU - Mcmillan, Andrew

AU - Moorman, Anthony V.

AU - Richards, Susan M.

AU - Rowe, Jacob M.

AU - Tallman, Martin S.

AU - Goldstone, Anthony H.

PY - 2012/5

Y1 - 2012/5

N2 - Although the incidence rate of acute lymphoblastic leukaemia (ALL) is slightly higher in older than in younger adults, response rates to induction chemotherapy and survival rates are poorer. The contribution of disease-related versus treatment-related factors remains unclear. We analysed 100 older patients (aged 55-65 years) treated on the UKALLXII/ECOG2993 trial compared with 1814 younger patients (aged 14-54 years). Baseline characteristics, induction chemotherapy course, infections, drug reductions and survival outcomes were compared. There were more Philadelphia-positive (Ph+) patients in the older group (28% vs. 17%, P = 0·02), and a trend towards higher combined cytogenetic risk score (46% vs. 35%, P = 0·07). The complete remission rate in older patients was worse (73% vs. 93%, P < 0·0001) as was 5-year overall survival (21% vs. 41%, P < 0·0001) and event-free survival (EFS) (19% vs. 37%, P < 0·0001). Older patients had more infections during induction (81% vs. 70%, P = 0·05), and drug reductions (46% vs. 28%, P = 0·0009). Among older patients, Ph+ and cytogenetic risk category as well as infection during induction predicted for worse EFS. Poorer outcomes in these patients are partly due to cytogenetic risk, but there is significant morbidity and mortality during induction chemotherapy with frequent delays and drug reductions. New approaches, including better risk stratification and use of targeted therapies, could improve treatment for these patients.

AB - Although the incidence rate of acute lymphoblastic leukaemia (ALL) is slightly higher in older than in younger adults, response rates to induction chemotherapy and survival rates are poorer. The contribution of disease-related versus treatment-related factors remains unclear. We analysed 100 older patients (aged 55-65 years) treated on the UKALLXII/ECOG2993 trial compared with 1814 younger patients (aged 14-54 years). Baseline characteristics, induction chemotherapy course, infections, drug reductions and survival outcomes were compared. There were more Philadelphia-positive (Ph+) patients in the older group (28% vs. 17%, P = 0·02), and a trend towards higher combined cytogenetic risk score (46% vs. 35%, P = 0·07). The complete remission rate in older patients was worse (73% vs. 93%, P < 0·0001) as was 5-year overall survival (21% vs. 41%, P < 0·0001) and event-free survival (EFS) (19% vs. 37%, P < 0·0001). Older patients had more infections during induction (81% vs. 70%, P = 0·05), and drug reductions (46% vs. 28%, P = 0·0009). Among older patients, Ph+ and cytogenetic risk category as well as infection during induction predicted for worse EFS. Poorer outcomes in these patients are partly due to cytogenetic risk, but there is significant morbidity and mortality during induction chemotherapy with frequent delays and drug reductions. New approaches, including better risk stratification and use of targeted therapies, could improve treatment for these patients.

KW - Acute lymphoblastic leukaemia

KW - Chemotherapy

KW - Elderly

KW - Infection

UR - http://www.scopus.com/inward/record.url?scp=84860012521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860012521&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2012.09095.x

DO - 10.1111/j.1365-2141.2012.09095.x

M3 - Article

VL - 157

SP - 463

EP - 471

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -